Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
49.75%
Operating Margin
29.65%
Net Margin
12.24%
Efficiency Metrics
Revenue per Expense Ratio
1.42
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
31.79%
Income Tax Rate
-173.49%
EPS
2.1200000000
Balance Sheet Analysis
Current Ratio
1.76
Cash Ratio
0.71
Working Capital
$20.74B
Debt to Equity
0.60
Debt to Assets
23.65%
Equity Ratio
39.41%
Cash Flow Analysis
Operating Cash Flow Ratio
22.18%
Free Cash Flow Ratio
11.09%
CapEx to Revenue
11.09%
Dividends Paid
$864.19M
Stock Buybacks
$2.19B
Total Shareholder Returns
$3.06B
Cash Position Change
-2.48%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Detailed Growth Metrics
Core Performance
Revenue
9.05%
Net Income
71.59%
EPS
68.89%
Operating Income
93.78%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
108.93%
Operating Cash Flow
-11.13%
Free Cash Flow
116.93%
Balance Sheet Health
Assets
-1.17%
Debt
3.27%
Book Value per Share
-7.06%
Inventory
-66.05%
Shareholder Returns
Dividends per Share
-46.79%
Shares Outstanding
8.99%
Long Term Trends
3Y Revenue/Share
-8.67%
5Y Revenue/Share
-6.10%
3Y Dividend/Share
-76.19%
5Y Dividend/Share
745.63%